Camurus AB (publ) (CAMX.ST) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. CAMX.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.61% | 30.00% | Pass |
| Interest-bearing investments | 10.64% | 30.00% | Pass |
| Non-permissible income | 2.86% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.47% | 33.00% | Pass |
| Interest-bearing investments | 78.61% | 33.00% | Fail |
| Non-liquid assets | 12.33% | at least 20.00% | Fail |
| Non-permissible income | 2.86% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.47% | 33.33% | Pass |
| Cash + interest-bearing securities | 78.61% | 33.33% | Fail |
| Accounts receivable | 87.67% | 33.33% | Fail |
| Non-permissible income | 2.86% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.47% | 33.33% | Pass |
| Cash + interest-bearing securities | 78.61% | 33.33% | Fail |
| Accounts receivable | 87.67% | 50.00% | Fail |
| Non-permissible income | 2.86% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.61% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.65% | 33.00% | Pass |
| Accounts receivable | 1.23% | 33.00% | Pass |
| Non-permissible income | 2.86% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.65% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.46% | 49.00% | Pass |
| Accounts receivable | 1.32% | 49.00% | Pass |
| Non-permissible income | 2.86% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.65% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.46% | 33.33% | Pass |
| Accounts receivable | 12.78% | 49.00% | Pass |
| Non-permissible income | 2.86% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 45.00 | NEUTRAL |
| Stochastic %K (14) | 32.00 | NEUTRAL |
| CCI (20) | -87.61 | NEUTRAL |
| Williams %R (14) | -68.00 | NEUTRAL |
| MACD (12,26,9) | -2.82 | SELL |
| ROC (10) | -2.47 | SELL |
| Momentum (10) | -15.00 | SELL |
| EMA (10) | 595.36 | SELL |
| SMA (10) | 593.10 | SELL |
| EMA (20) | 600.60 | SELL |
| SMA (20) | 607.02 | SELL |
| EMA (30) | 600.91 | SELL |
| SMA (30) | 608.02 | SELL |
| EMA (50) | 595.02 | SELL |
| SMA (50) | 602.65 | SELL |
| EMA (100) | 582.17 | BUY |
| SMA (100) | 570.04 | BUY |
| EMA (200) | 592.39 | SELL |
| SMA (200) | 572.05 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.